Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines

被引:158
作者
Parker, Anne [1 ]
Bowles, Kristin [2 ]
Bradley, J. Andrew [3 ]
Emery, Vincent [4 ,5 ]
Featherstone, Carrie [1 ]
Gupte, Girish [6 ]
Marcus, Robert [7 ]
Parameshwar, Jayan [8 ]
Ramsay, Alan [9 ]
Newstead, Charles [10 ]
机构
[1] Beatson, W Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England
[3] Addenbrookes Hosp, Cambridge, England
[4] Royal Free Hosp, London NW3 2QG, England
[5] UCL, London, England
[6] Birmingham Childrens Hosp, Birmingham, W Midlands, England
[7] Kings Coll Hosp London, London, England
[8] Papworth Hosp, Cambridge CB3 8RE, England
[9] Univ Coll Hosp, London, England
[10] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
关键词
lymphoproliferative; transplant; therapy; chemotherapy; MONOCLONAL-ANTIBODY RITUXIMAB; DOSE-ADJUSTED EPOCH; B-CELL LYMPHOMAS; ANTI-CD20; ANTIBODY; ELDERLY-PATIENTS; ARGININE BUTYRATE; HODGKINS-DISEASE; CHEMOTHERAPY; THERAPY; RETRANSPLANTATION;
D O I
10.1111/j.1365-2141.2010.08160.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
引用
收藏
页码:693 / 705
页数:13
相关论文
共 89 条
  • [1] Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry
    Aull, MJ
    Buell, JF
    Trofe, J
    First, MR
    Alloway, RR
    Hanaway, MJ
    Wagoner, L
    Gross, TG
    Beebe, T
    Woodle, ES
    [J]. TRANSPLANTATION, 2004, 78 (11) : 1676 - 1682
  • [2] Maltoma:: A Helicobacter pylori-associated malignancy in transplant patients -: A report from the Israel Penn International Transplant Tumor Registry with a review of published literature
    Aull, MJ
    Buell, JF
    Peddi, VR
    Trofe, J
    Beebe, TM
    Hanaway, MJ
    Roy-Chaudhury, P
    Alloway, RR
    First, MR
    Woodle, ES
    [J]. TRANSPLANTATION, 2003, 75 (02) : 225 - 228
  • [3] Lymphoproliferative disorders in Oxford renal transplant recipients
    Bates, WD
    Gray, DWR
    Dada, MA
    Chetty, R
    Gatter, KC
    Davies, DR
    Morris, PJ
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (06) : 439 - 446
  • [4] Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients
    Berney, T
    Delis, S
    Kato, T
    Nishida, S
    Mittal, NK
    Madariaga, J
    Levi, D
    Nery, NR
    Cirocco, RE
    Gelman, B
    Ruiz, P
    Tzakis, AG
    [J]. TRANSPLANTATION, 2002, 74 (07) : 1000 - 1006
  • [5] Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: Duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation
    Birkeland, SA
    Hamilton-Dutoit, S
    Bendtzen, K
    [J]. TRANSPLANTATION, 2003, 76 (01) : 153 - 158
  • [6] qRituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation - Results of a phase II trial
    Blaes, AH
    Peterson, BA
    Bartlett, N
    Dunn, DL
    Morrison, VA
    [J]. CANCER, 2005, 104 (08) : 1661 - 1667
  • [7] Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study
    Buadi, Francis K.
    Heyman, Meyer R.
    Gocke, Christopher D.
    Rapoport, Aaron P.
    Hakimian, Roger
    Bartlett, Stephen T.
    Sarkodee-Adoo, Clarence
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (03) : 208 - 214
  • [8] Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement
    Buell, JF
    Gross, TG
    Hanaway, MJ
    Trofe, J
    Roy-Chaudhury, P
    First, MR
    Woodle, ES
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 954 - 955
  • [9] Monoclonal antibody therapy for lymphoma
    Campbell, P
    Marcus, R
    [J]. BLOOD REVIEWS, 2003, 17 (03) : 143 - 152
  • [10] CARBONE PP, 1971, CANCER RES, V31, P1860